Last reviewed · How we verify

NCT03346668

Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia

Completed EARLY_PHASE1 Last updated 25 March 2024
What this trial tests

EARLY_PHASE1 trial testing Topical gabapentin in Scarring Alopecia in 5 participants. Completed in 11 October 2021.

Timeline
28 January 2016
Primary endpoint
11 October 2021
11 October 2021

Quick facts

Lead sponsorUniversity of Minnesota
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment5
Start date28 January 2016
Primary completion11 October 2021
Estimated completion11 October 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Minnesota

Who can join

18 and older, any sex, with Scarring Alopecia or Frontal Fibrosing Alopecia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will serve as a pilot study to determine the efficacy and safety of topical gabapentin in the treatment of symptomatic scarring alopecia.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Oral gabapentin for scalp pruritus in patients with lichen planopilaris: A case series.
    Chen LC, Ogbutor C, Yıldız-Altay Ü, Kelley KJ, et al · · 2024 · PMID 39233792 · DOI 10.1016/j.jdcr.2024.06.022
  2. Topical gabapentin and its relation to cutaneous innervation in symptomatic lymphocytic primary cicatricial alopecia
    Bohjanen S, McAdams B, Mead N, Loavenbruck A, et al · · 2024

Verify or expand the search:

Other University of Minnesota trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03346668.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing